SEC Form 4 filed by Director Spiegel Gary
$LUNA
Biotechnology: Commercial Physical & Biological Resarch
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
LUNA INNOVATIONS INC [ LUNA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 10/01/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Units | (1) | 10/01/2024 | A | 1,971.83(2) | (3) | (3) | Common Stock | 1,971.83 | $0 | 62,184.41 | D | ||||
| Stock Units | (1) | 10/01/2024 | A | 704.23(4) | (3) | (3) | Common Stock | 704.23 | $0 | 62,888.64 | D | ||||
| Stock Units | (1) | 10/01/2024 | A | 234.74(5) | (3) | (3) | Common Stock | 234.74 | $0 | 63,123.38 | D | ||||
| Explanation of Responses: |
| 1. Stock Units are convertible into issuer's common stock on a 1-for-1 basis. |
| 2. This grant was made pursuant to the issuer's non-employee director compensation policy, as compensation for Mr. Spiegel's service as a member of the board of directors for the period from October 1, 2024 to December 31, 2024. The number of stock units is equal to $4,200.00, the portion of their fees the Reporting person elected to receive in stock units, divided by $2.13, the closing price of the issuer's common stock on the Nasdaq Capital Market October 1, 2024, the first trading day of the quarter. |
| 3. The stock units become issuable in common stock of the issuer at the election of the Reporting Person upon the earliest to occur of the Reporting Person's termination of service, a change in control of the issuer, an unforeseeable emergency, or a fixed selected by the Reporting Person. The units have no expiration date. |
| 4. This grant was made pursuant to issuer's non-employee director compensation policy, as compensation for Mr. Spiegel's service as the chairman of the compensation committee of the board of directors for the period from October 1, 2024 to December 31, 2024. The number of stock units is equal to $1,500.00, the portion of their fees the Reporting Person elected to receive in stock units, divided by $2.13, the closing price of issuer's common stock on the Nasdaq Capital Market on October 1, 2024, the first trading day of the quarter. |
| 5. This grant was made pursuant to issuer's non-employee director compensation policy, as compensation for Mr. Spiegel's service on the nominating and governance committee of the board of directors for the period from October 1, 2024 to December 31, 2024. The number of stock units is equal to $500.00, the portion of their fees the Reporting Person elected to receive in stock units, divided by $2.13, the closing price of issuer's common stock on the Nasdaq Capital Market on October 1, 2024, the first trading day of the quarter. |
| Remarks: |
| /s/ Ryan Stewart, Attorney-In-Fact | 10/03/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||